Global Uveitis Treatment Market (2019 to 2026) - by Drug Class, Disease Type and Distribution Channel - ResearchAndMarkets.com

DUBLIN--()--The "Uveitis Treatment Market by Drug Class, Disease Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

The global uveitis treatment market was valued at $478 million in 2018, and is projected to reach $687 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in the treatment of uveitis. Different types of uveitis include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. The most common type of uveitis is an inflammation of iris called iritis or anterior uveitis. Uveitis can be serious, leading to permanent vision loss.

The uveitis treatment market is expected to experience significant growth during the forecast period, owing to increase in prevalence of uveitis, rise in popularity of advanced therapeutics, and wide availability of drugs. In addition, early detection of the disease and surge in R&D activities to developed ideal therapeutics further fuel the market growth. However, unknown etiology and pathophysiology of uveitis and adverse effects associated with the treatment therapeutics may hamper the market growth.

The global uveitis treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, the market is classified into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report. According to distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key Benefits

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Key Players Profiled

  • AbbVie Inc.
  • Alimera Sciences, Inc.
  • Allergan Plc.
  • Amgen Inc.
  • Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis AG
  • Santen Pharmaceutical Co., Ltd.

Key Topics Covered:

1. INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

2. EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. Key findings

2.2.1. Top investment pockets

2.2.2. Market player positioning, 2018

2.3. CXO perspective

3. MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key forces shaping uveitis treatment industry/market

3.2.1. Moderate power of suppliers

3.2.2. High threat of new entrants

3.2.3. High threat of substitution

3.2.4. Moderate competitive rivalry

3.2.5. Moderate bargaining power of buyers

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1. Increase in prevalence of uveitis

3.3.1.2. Potential drugs in pipeline

3.3.1.3. Surge in healthcare expenditure worldwide

3.3.2. Restraint

3.3.2.1. Unknown etiology of uveitis

3.3.3. Opportunities

3.3.3.1. Growth opportunities in emerging markets

3.3.3.2. Higher number of unmet needs for treatment of uveitis

3.3.4. Impact analysis

4. UVEITIS TREATMENT MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Anti-inflammatory

4.3. Antimicrobial drugs

4.4. Immunotherapy & targeted therapies

4.5. Others

5. UVEITIS TREATMENT MARKET, BY DISEASE TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Anterior uveitis

5.3. Posterior uveitis

5.4. Intermediate uveitis

5.5. Panuveitis

6. UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals pharmacies

6.3. Drug stores and retail pharmacies

6.4. Online pharmacies

7. UVEITIS TREATMENT MARKET, BY REGION

7.1. Overview

7.2. North America

7.3. Europe

7.4. Asia-Pacific

7.5. LAMEA

8. COMPANY PROFILES

For more information about this report visit https://www.researchandmarkets.com/r/fksvi9

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900